{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:01:11Z","timestamp":1779926471233,"version":"3.53.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01544-4","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:12:03Z","timestamp":1737634323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab\u2014a polish multicenter, observational study"],"prefix":"10.1007","volume":"25","author":[{"given":"Renata","family":"Pacholczak-Madej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Drobniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Grela-Wojewoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Calik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Versuti","family":"Viegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Tusie\u0144-Ma\u0142ecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Dobrza\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Szwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Gawlik-Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Walocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Blecharz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Stok\u0142osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"Puskulluoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"1544_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up 5 behalf of the ESMO guidelines committee. Ann Oncol. 2024;35:692\u2013706.","journal-title":"Ann Oncol"},{"key":"1544_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/OP.22.00660","volume":"19","author":"EA Singer","year":"2023","unstructured":"Singer EA, Rumble RB, Van Veldhuizen PJ. Management of metastatic clear cell renal cell carcinoma: ASCO guideline Q&A. JCO Oncol Pract. 2023;19:127\u201331.","journal-title":"JCO Oncol Pract"},{"key":"1544_CR3","doi-asserted-by":"crossref","unstructured":"Wysocki PJ, Ch\u0142osta P, Chrzan R, et al (2022) WYTYCZNE POST\u0118POWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO Zalecenia post\u0119powania diagnostyczno-terapeutycznego w raku nerkowokom\u00f3rkowym-aktualizacja Polish Society of Clinical Oncology and Polish Urological Association guidelines for the diagnosis and treatment of renal cell cancer-update. 6:424\u2013457","DOI":"10.5603\/OCP.2020.0029"},{"key":"1544_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DYC Heng","year":"2013","unstructured":"Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141\u20138.","journal-title":"Lancet Oncol"},{"key":"1544_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5: e001079.","journal-title":"ESMO Open"},{"key":"1544_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1200\/JCO.2024.42.4_suppl.363","volume":"42","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Escudier B, McDermott DF, et al. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial. J Clin Oncol. 2024;42:363\u2013363.","journal-title":"J Clin Oncol"},{"key":"1544_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-018-0698-5","volume":"18","author":"Y Mao","year":"2018","unstructured":"Mao Y, Chen D, Duan S, Zhao Y, Wu C, Zhu F, Chen C, Chen Y. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int. 2018;18:1.","journal-title":"Cancer Cell Int"},{"key":"1544_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI: J Nat Cancer Inst. 2014. https:\/\/doi.org\/10.1093\/jnci\/dju124.","journal-title":"JNCI: J Nat Cancer Inst"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"22089","DOI":"10.1038\/srep22089","volume":"6","author":"X Gu","year":"2016","unstructured":"Gu X, Gao X, Li X, Qi X, Ma M, Qin S, Yu H, Sun S, Zhou D, Wang W. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep. 2016;6:22089.","journal-title":"Sci Rep"},{"key":"1544_CR10","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/ijc.28536","volume":"134","author":"MX Li","year":"2014","unstructured":"Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134:2403\u201313.","journal-title":"Int J Cancer"},{"key":"1544_CR11","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530\u201340.","journal-title":"J Clin Oncol"},{"key":"1544_CR12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, \u0160eruga B, Oca\u00f1a A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2014;23:1204\u201312.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11523-019-00660-6","volume":"14","author":"H Ishihara","year":"2019","unstructured":"Ishihara H, Tachibana H, Takagi T, et al. Predictive impact of peripheral blood markers and C-reactive protein in nivolumab therapy for metastatic renal cell carcinoma. Target Oncol. 2019;14:453\u201363.","journal-title":"Target Oncol"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cca.2018.02.014","volume":"480","author":"Z Wang","year":"2018","unstructured":"Wang Z, Peng S, Wang A, Xie H, Guo L, Jiang N, Niu Y. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma. Clin Chim Acta. 2018;480:166\u201372.","journal-title":"Clin Chim Acta"},{"key":"1544_CR15","unstructured":"Obwieszczenie Ministra Zdrowia z dnia 18 marca 2024 r. w sprawie wykazu refundowanych lek\u00f3w, \u015brodk\u00f3w spo\u017cywczych specjalnego przeznaczenia \u017cywieniowego oraz wyrob\u00f3w medycznych na 1 kwietnia 2024 r. - Ministerstwo Zdrowia - Portal Gov.pl. https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenie-ministra-zdrowia-z-dnia-18-marca-2024-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych. Accessed 19 May 2024"},{"key":"1544_CR16","unstructured":"Nivolumab- SUMMARY OF PRODUCT CHARACTERISTICS . https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed 16 Jun 2022"},{"key":"1544_CR17","unstructured":"Ipilimumab- SUMMARY OF PRODUCT CHARACTERISTICS . https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf. Accessed 16 Jun 2022"},{"key":"1544_CR18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1259\/bjr.20170457","volume":"91","author":"B Somarouthu","year":"2018","unstructured":"Somarouthu B, Lee SI, Urban T, Sadow CA, Harris GJ, Kambadakone A. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol. 2018;91:736.","journal-title":"Br J Radiol"},{"key":"1544_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10147-019-01528-5","volume":"25","author":"K Suzuki","year":"2020","unstructured":"Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 2020;25:135\u201344.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"1544_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbcan.2010.06.002","volume":"1806","author":"M Kowalewska","year":"2010","unstructured":"Kowalewska M, Nowak R, Chechlinska M. Implications of cancer-associated systemic inflammation for biomarker studies. Biochim et Biophys Acta (BBA) - Rev Cancer. 2010;1806(2):163\u201371. https:\/\/doi.org\/10.1016\/j.bbcan.2010.06.002.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"key":"1544_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell. 2009;16:183\u201394.","journal-title":"Cancer Cell"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883\u201399.","journal-title":"Cell"},{"key":"1544_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7150\/jca.5482","volume":"4","author":"YG Man","year":"2013","unstructured":"Man YG, Stojadinovic A, Mason J, et al. Tumor-Infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer. 2013;4:84\u201395.","journal-title":"J Cancer"},{"key":"1544_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152500","volume":"11","author":"Y Mao","year":"2016","unstructured":"Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PLoS ONE. 2016;11: e0152500.","journal-title":"PLoS ONE"},{"key":"1544_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.canlet.2008.03.028","volume":"267","author":"A Sica","year":"2008","unstructured":"Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267:204\u201315.","journal-title":"Cancer Lett"},{"key":"1544_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","volume":"24","author":"D Schumacher","year":"2013","unstructured":"Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24:130\u20137.","journal-title":"Cancer Cell"},{"key":"1544_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1393134","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, Marone G, Schiavoni G. Eosinophils: the unsung heroes in cancer? OncoImmunology. 2018. https:\/\/doi.org\/10.1080\/2162402X.2017.1393134.","journal-title":"OncoImmunology"},{"key":"1544_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2174\/0929867323666160119094313","volume":"23","author":"S Sakkal","year":"2016","unstructured":"Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavourable? Curr Med Chem. 2016;23:650\u201366.","journal-title":"Curr Med Chem"},{"key":"1544_CR29","doi-asserted-by":"publisher","first-page":"44039","DOI":"10.18632\/oncotarget.9836","volume":"7","author":"N Na","year":"2016","unstructured":"Na N, Yao J, Cheng C, et al. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors. Oncotarget. 2016;7:44039\u201346.","journal-title":"Oncotarget"},{"key":"1544_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.urolonc.2017.01.016","volume":"35","author":"R Boissier","year":"2017","unstructured":"Boissier R, Campagna J, Branger N, Karsenty G, Lechevallier E. The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: a review. Urol Oncol: Semin Orig Invest. 2017;35:135\u201341.","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"1544_CR31","doi-asserted-by":"publisher","first-page":"84506","DOI":"10.18632\/oncotarget.21108","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Su S, Guo Y, Wang X, Su S, Guo Y. The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8:84506\u201314.","journal-title":"Oncotarget"},{"key":"1544_CR32","doi-asserted-by":"publisher","first-page":"175883592110196","DOI":"10.1177\/17588359211019642","volume":"13","author":"SE Rebuzzi","year":"2021","unstructured":"Rebuzzi SE, Signori A, Banna GL, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol. 2021;13:17588359211019642.","journal-title":"Ther Adv Med Oncol"},{"key":"1544_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100634","volume":"7","author":"SE Rebuzzi","year":"2022","unstructured":"Rebuzzi SE, Signori A, Buti S, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian expanded access program. ESMO Open. 2022;7: 100634.","journal-title":"ESMO Open"},{"key":"1544_CR34","doi-asserted-by":"publisher","first-page":"239.e17","DOI":"10.1016\/j.urolonc.2020.12.020","volume":"39","author":"E Roussel","year":"2021","unstructured":"Roussel E, Kinget L, Verbiest A, Debruyne PR, Baldewijns M, Van Poppel H, Albersen M, Beuselinck B. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. Urol Oncol: Semin Orig Invest. 2021;39:239.e17-239.e25.","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"1544_CR35","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/j.clgc.2017.12.015","volume":"16","author":"MA Bilen","year":"2018","unstructured":"Bilen MA, Dutcher GMA, Liu Y, Ravindranathan D, Kissick HT, Carthon BC, Kucuk O, Harris WB, Master VA. Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clin Genitourin Cancer. 2018;16:e563\u201375.","journal-title":"Clin Genitourin Cancer"},{"key":"1544_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.746976","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Meng F, Jiang R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021;11: 746976.","journal-title":"Front Oncol"},{"key":"1544_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-017-0287-5","volume":"5","author":"G Jeyakumar","year":"2017","unstructured":"Jeyakumar G, Kim S, Bumma N, Landry C, Silski C, Suisham S, Dickow B, Heath E, Fontana J, Vaishampayan U. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5:82.","journal-title":"J Immunother Cancer"},{"key":"1544_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jcm10225325","volume":"10","author":"K Iinuma","year":"2021","unstructured":"Iinuma K, Enomoto T, Kawada K, et al. Utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with Nivolumab and Ipilimumab. J Clin Med. 2021;10:10.","journal-title":"J Clin Med"},{"key":"1544_CR39","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.3390\/cancers14225659","volume":"14","author":"Y Yano","year":"2022","unstructured":"Yano Y, Ohno T, Komura K, et al. Serum C-reactive protein level predicts overall survival for clear cell and non-clear cell renal cell carcinoma treated with Ipilimumab plus Nivolumab. Cancers (Basel). 2022;14:5659.","journal-title":"Cancers (Basel)"},{"key":"1544_CR40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10147-024-02538-8","volume":"29","author":"K Numakura","year":"2024","unstructured":"Numakura K, Sekine Y, Osawa T, et al. The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy. Int J Clin Oncol. 2024;29:1019\u201326.","journal-title":"Int J Clin Oncol"},{"key":"1544_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-021-00334-4","volume":"9","author":"MD Tucker","year":"2021","unstructured":"Tucker MD, Brown LC, Chen Y-W, et al. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021;9:80.","journal-title":"Biomark Res"},{"key":"1544_CR42","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2340\/1651-226X.2024.40390","volume":"63","author":"Y Beulque","year":"2024","unstructured":"Beulque Y, Kinget L, Roussel E, et al. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab\/nivolumab. Acta Oncol. 2024;63:658\u201368.","journal-title":"Acta Oncol"},{"key":"1544_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.eururo.2016.02.033","volume":"70","author":"AJ Templeton","year":"2016","unstructured":"Templeton AJ, Knox JJ, Lin X, et al. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol. 2016;70:358\u201364.","journal-title":"Eur Urol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01544-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:59Z","timestamp":1764917519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01544-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01544-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5313520\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the supplementary file has been updated","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RPM has received travel grants from Accord, BMS, MSD, and lecture fees from Astra Zeneca, BMS, GSK, Novartis, Roche, MSD; AD has received travel grants and lecture fees from Roche, BMS, Janssen, Molteni, MSD, Accord;  AGW has received travel grants and lecture fees from Roche, Novaris, Lili, Astellas, Pfizer, Amgen, Swixx, Pierre Fabre, Egis, BMS, MSD; JC has received lecture fees from BMS; NVV has no financial interests; DTM has received travel grants and lecture fees from MSD, Pierre Fabre, BMS, Novartis, Pfizer; JD has received travel grants and lecture fees from Amgen, AstraZeneca, BMS, MSD, Novartis, Nutricia;  AR has received travel grants and lecture fees from Roche, BMS, Ipsen, Pfizer, Novartis, Gilead, MSD; AB has received travel grants and lecture fees from BMS, MSD, Astellas, Merck, Servier, Astra Zeneca, Pfizer; MS has received travel grants and lecture fees from Roche, BMS, Janssen,  MSD, Amgen, Astellas., Ipsen, Pfizer, Novartis, Gilead; AGU has received travel grants from GSK, Lilly, Astra Zeneca, Gilead, Accord, and lecture fees from Astra Zeneca. JW has no financial interests; PB has received travel grants, lecture fees, and advisory boards from AstraZeneca, MSD, GSK, Pharma; \u0141S has received travel grants from BMS, Accord; MP has received travel grants and lecture fees from AstraZeneca, Roche, Novartis, Elli Lilly, Janssen, Gilead, and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of\u00a0Jagiellonian University Medical College (approval number 118.0043.1.115.2024, dated April 19, 2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed, institutional consent was obtained from all individual participants included in the study before starting treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"45"}}